BIO Submits Comments on EPA Renewables Enhancement and Growth Support Rule

The Biotechnology Innovation Organization (BIO) today submitted comments on the Environmental Protection Agency’s recently proposed Renewables Enhancement and Growth Support (REGS) Rule. BIO supports EPA’s ongoing efforts to improve the efficiency and effectiveness of the federal Renewable Fuel Standards (RFS).

BIO Statement on National Academies’ Consensus Study on Human Gene Editing

Biotechnology Innovation Organization (BIO) President and CEO James C. Greenwood issued the following statement  regarding the Consensus Study on Human Gene Editing, released today by the Human Gene Editing Initiative of the National Academies of Sciences and Medicine (NAS/NAM)

EU’s Anti-Science Comitology Reform Threatens Innovation

Washington, D.C. (February 14, 2017) – The European Commission announced today a proposal to revise its Comitology Regulation forcing policy decisions to individual EU member countries.

BIO Announces Gary Andres as the New Senior Executive Vice President of Public Affairs

Long-time Majority Staff Director of the House Energy and Commerce Committee Dr. Gary Andres joins BIO as Senior Executive Vice President of Public Affairs.

Registration Now Open for the 14th Annual BIO World Congress on Industrial Biotechnology

BIO announced registration and housing are now open for the 2017 World Congress on Industrial Biotechnology.  The conference will be held July 23-26, 2017 at the Palais des congrès de Montréal in Montréal, Canada. 

BIO Statement on President Trump’s Comments Supporting Biopharmaceutical Competition and Innovation

Washington, DC (January 31, 2017) – BIO issued the following statement regarding President Trump’s comments today supporting biopharmaceutical innovation:

BIO Submits Comments on FDA proposed rule: Good Laboratory Practice for Nonclinical Laboratory Studies

RE: Docket No. FDA-2010-N-0548: The Biotechnology Innovation Organization (BIO) appreciates the opportunity to offer comments to Food and Drug Administration (FDA)’s “Good Laboratory Practice for Nonclinical Laboratory Studies.” 

BIO Statement on USDA and FDA Actions related to Pre-market Regulatory Oversight of Plant and Animal Organisms

The U.S. Department of Agriculture (USDA) and the U.S. Food and Drug Administration (FDA) published today four documents related to the pre-market regulatory oversight of a variety of biology-based agricultural tools, including genetically engineered plants and plants and animals derived from certain newer precision breeding techniques, such as genome editing.

BIO’s Jim Greenwood Meets with India’s PM Modi

Delivers Message: India Must Protects Innovators’ Work Product

BIO Statement on Proposed Maryland Drug Pricing Legislation

BIO's statement  regarding proposed drug pricing legislation within the Maryland Senate.